Mood Effects of Serotonin Agonists Extended
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- University of Chicago
- Enrollment
- 56
- Locations
- 1
- Primary Endpoint
- DASS-21
Study Overview
Brief Summary
In this study we are examining the effects of repeated very low doses of serotonin agonists on mood individuals with negative mood.
Detailed Description
Here, we are examining the effects of four repeated low doses of lysergic acid diethylamide (LSD), compared to placebo, administered to healthy adults at 3-4 day intervals, on mood, cognitive performance and responses to emotional tasks
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Triple (Participant, Care Provider, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •English fluency
- •High school level education
- •BMI between 19 and 30
Exclusion Criteria
- •Diagnosed medical condition
- •women who are nursing, pregnant, or plan to become pregnant within 3 months
- •History of psychotic disorder or family history of psychotic disorder
Arms & Interventions
Placebo
Placebo
Intervention: Placebo (Drug)
Serotonin agonist 13ug
13ug of serotonin agonist
Intervention: Serotonin agonist - 13ug (Drug)
Serotonin agonist 26ug
26ug of serotonin agonist
Intervention: Serotonin agonist - 26ug (Drug)
Outcomes
Primary Outcomes
DASS-21
Time Frame: End of session 5, approximately 2 weeks from baseline
The primary outcome measure is the depression anxiety and stress scale (DASS) 21. This self-report measure contains 21 items and the range of scores for depression is 0-42, anxiety 0-42, and stress 0-42. Our primary outcome measure is total depression scale ratings during session 5, with lower scores indicating lower ratings of depression.
Secondary Outcomes
No secondary outcomes reported